Q3166008 (Q3166008): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the materialized bot - inferring region from the coordinates) |
(Created claim: summary (P836): B-cell non-Hodgkin lymphomas (NHL) constitute a very heterogeneous group of malignant lymphoproliferative diseases, both biologically and clinically, consisting of more than 40 neoplasms ranging from indolent to highly aggressive diseases. Although survival after chemotherapeutic treatment has increased in recent years, some patients with B-cell NHL are relapsed due to drug resistance, presenting unfavorable prognosis, so the identification of n...) |
||||||||||||||
| Property / summary | |||||||||||||||
B-cell non-Hodgkin lymphomas (NHL) constitute a very heterogeneous group of malignant lymphoproliferative diseases, both biologically and clinically, consisting of more than 40 neoplasms ranging from indolent to highly aggressive diseases. Although survival after chemotherapeutic treatment has increased in recent years, some patients with B-cell NHL are relapsed due to drug resistance, presenting unfavorable prognosis, so the identification of new prognostic markers and therapeutic targets is urgent. Podocalicin (PCLP1), a molecule involved in tumor adhesion and invasion, is abnormally expressed in various types of tumors and is associated with the most aggressive types of cancer. PCLP1 contributes to the proliferation and survival of Raji cells of Burkitt lymphoma, a type of NHL B cells. The objective of this project is to study the involvement of PCLP1 in the development of different types of B-cell NHL and the underlying mechanisms. To do this, the expression of PCLP1 will be determined in samples of patients presenting these neoplasms by flow cytometry, as well as their correlation with the clinical and pathological characteristics of the patients. In addition, the effect of PCLP1 expression on cell proliferation and viability and resistance to chemotherapeutic agents will be analysed. Finally, the role of PCLP1 in metabolic reprogramming of B-cell NHL will be evaluated by determining metabolites and enzymes induced by the expression of this protein by mass spectrometry and immunotranference and by using specific metabolic route inhibitors. This study will assess the usefulness of PCLP1 as a diagnostic and prognostic marker and as a possible therapeutic target in these diseases. (English) | |||||||||||||||
| Property / summary: B-cell non-Hodgkin lymphomas (NHL) constitute a very heterogeneous group of malignant lymphoproliferative diseases, both biologically and clinically, consisting of more than 40 neoplasms ranging from indolent to highly aggressive diseases. Although survival after chemotherapeutic treatment has increased in recent years, some patients with B-cell NHL are relapsed due to drug resistance, presenting unfavorable prognosis, so the identification of new prognostic markers and therapeutic targets is urgent. Podocalicin (PCLP1), a molecule involved in tumor adhesion and invasion, is abnormally expressed in various types of tumors and is associated with the most aggressive types of cancer. PCLP1 contributes to the proliferation and survival of Raji cells of Burkitt lymphoma, a type of NHL B cells. The objective of this project is to study the involvement of PCLP1 in the development of different types of B-cell NHL and the underlying mechanisms. To do this, the expression of PCLP1 will be determined in samples of patients presenting these neoplasms by flow cytometry, as well as their correlation with the clinical and pathological characteristics of the patients. In addition, the effect of PCLP1 expression on cell proliferation and viability and resistance to chemotherapeutic agents will be analysed. Finally, the role of PCLP1 in metabolic reprogramming of B-cell NHL will be evaluated by determining metabolites and enzymes induced by the expression of this protein by mass spectrometry and immunotranference and by using specific metabolic route inhibitors. This study will assess the usefulness of PCLP1 as a diagnostic and prognostic marker and as a possible therapeutic target in these diseases. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: B-cell non-Hodgkin lymphomas (NHL) constitute a very heterogeneous group of malignant lymphoproliferative diseases, both biologically and clinically, consisting of more than 40 neoplasms ranging from indolent to highly aggressive diseases. Although survival after chemotherapeutic treatment has increased in recent years, some patients with B-cell NHL are relapsed due to drug resistance, presenting unfavorable prognosis, so the identification of new prognostic markers and therapeutic targets is urgent. Podocalicin (PCLP1), a molecule involved in tumor adhesion and invasion, is abnormally expressed in various types of tumors and is associated with the most aggressive types of cancer. PCLP1 contributes to the proliferation and survival of Raji cells of Burkitt lymphoma, a type of NHL B cells. The objective of this project is to study the involvement of PCLP1 in the development of different types of B-cell NHL and the underlying mechanisms. To do this, the expression of PCLP1 will be determined in samples of patients presenting these neoplasms by flow cytometry, as well as their correlation with the clinical and pathological characteristics of the patients. In addition, the effect of PCLP1 expression on cell proliferation and viability and resistance to chemotherapeutic agents will be analysed. Finally, the role of PCLP1 in metabolic reprogramming of B-cell NHL will be evaluated by determining metabolites and enzymes induced by the expression of this protein by mass spectrometry and immunotranference and by using specific metabolic route inhibitors. This study will assess the usefulness of PCLP1 as a diagnostic and prognostic marker and as a possible therapeutic target in these diseases. (English) / qualifier | |||||||||||||||
point in time: 12 October 2021
| |||||||||||||||
Revision as of 16:30, 12 October 2021
Project Q3166008 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3166008 in Spain |
Statements
33,250.0 Euro
0 references
66,500.0 Euro
0 references
50.0 percent
0 references
1 January 2019
0 references
31 March 2022
0 references
ASOCIACION INSTITUTO DE INVESTIGACION SANITARIA BIOCRUCES
0 references
43°17'43.73"N, 2°59'24.32"W
0 references
48013
0 references
Los linfomas no-Hodgkin (LNH) de células B constituyen un grupo de enfermedades malignas linfoproliferativas muy heterogéneo, tanto a nivel biológico como clínico, constituido por más de 40 neoplasias que abarcan desde enfermedades indolentes hasta altamente agresivas. Aunque la supervivencia tras tratamiento quimioterapéutico ha aumentado en los últimos años, algunos pacientes con LNH de células B sufren recaídas debido a la resistencia a fármacos, presentando pronóstico desfavorable, por lo que urge la identificación de nuevos marcadores pronósticos y dianas terapéuticas. La podocalicina (PCLP1), una molécula implicada en la adhesión e invasión tumorales, se expresa anormalmente en varios tipos de tumores y se asocia con los tipos de cáncer más agresivos. PCLP1 contribuye a la proliferación y supervivencia de las células Raji de linfoma de Burkitt, un tipo de LNH células B. El objetivo del presente proyecto es estudiar la implicación de PCLP1 en el desarrollo de diferentes tipos de LNH de células B y los mecanismos subyacentes. Para ello, se determinará la expresión de PCLP1 en muestras de pacientes que presentan estas neoplasias mediante citometría de flujo, así como su correlación con las características clínico-patológicas de los pacientes. Además, se analizará el efecto de la expresión de PCLP1 en la proliferación y viabilidad celulares y en la resistencia a agentes quimioterapéuticos. Finalmente, se evaluará el papel de PCLP1 en reprogramación metabólica de LNH de células B mediante la determinación de metabolitos y enzimas inducidos por la expresión de esta proteína por espectrometría de masas e inmunotranferencia y mediante el uso de inhibidores específicos de rutas metabólicas. Este estudio permitirá valorar la utilidad de PCLP1 como marcador diagnóstico y pronóstico y como posible diana terapéutica en estas enfermedades. (Spanish)
0 references
B-cell non-Hodgkin lymphomas (NHL) constitute a very heterogeneous group of malignant lymphoproliferative diseases, both biologically and clinically, consisting of more than 40 neoplasms ranging from indolent to highly aggressive diseases. Although survival after chemotherapeutic treatment has increased in recent years, some patients with B-cell NHL are relapsed due to drug resistance, presenting unfavorable prognosis, so the identification of new prognostic markers and therapeutic targets is urgent. Podocalicin (PCLP1), a molecule involved in tumor adhesion and invasion, is abnormally expressed in various types of tumors and is associated with the most aggressive types of cancer. PCLP1 contributes to the proliferation and survival of Raji cells of Burkitt lymphoma, a type of NHL B cells. The objective of this project is to study the involvement of PCLP1 in the development of different types of B-cell NHL and the underlying mechanisms. To do this, the expression of PCLP1 will be determined in samples of patients presenting these neoplasms by flow cytometry, as well as their correlation with the clinical and pathological characteristics of the patients. In addition, the effect of PCLP1 expression on cell proliferation and viability and resistance to chemotherapeutic agents will be analysed. Finally, the role of PCLP1 in metabolic reprogramming of B-cell NHL will be evaluated by determining metabolites and enzymes induced by the expression of this protein by mass spectrometry and immunotranference and by using specific metabolic route inhibitors. This study will assess the usefulness of PCLP1 as a diagnostic and prognostic marker and as a possible therapeutic target in these diseases. (English)
12 October 2021
0 references
Barakaldo
0 references
Identifiers
PI18_00629
0 references